STOCK TITAN

Treace Medical Concepts, Inc. Stock Price, News & Analysis

TMCI Nasdaq

Welcome to our dedicated page for Treace Medical Concepts news (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts stock.

Treace Medical Concepts, Inc. (TMCI) is a leader in 3D bunion correction and foot/ankle surgical solutions, delivering innovative technologies like the Lapiplasty system. This page provides timely updates on TMCI’s advancements in orthopedic medical devices, financial milestones, and clinical research.

Access press releases covering product launches, regulatory approvals, and partnerships that shape surgical practices. Investors will find earnings reports and strategic updates, while medical professionals can track procedural innovations and training opportunities.

Our curated news collection ensures you stay informed about TMCI’s contributions to reproducible surgical outcomes and cost-effective patient care. Content is verified for accuracy and relevance, offering a neutral perspective on company developments.

Bookmark this page for streamlined access to TMCI’s latest achievements in addressing complex deformities through evidence-based solutions. Regularly updated to reflect the company’s commitment to advancing orthopedic care.

Rhea-AI Summary

Treace Medical Concepts (NasdaqGS: TMCI), a medical technology company focused on surgical treatment of bunions and midfoot deformities through its Lapiplasty® and Adductoplasty® Procedures, announced its participation in the Stifel 2024 Healthcare Conference. The company's CEO John T. Treace and CFO Mark L. Hair will participate in a fireside chat on November 19, 2024, at 8:00 am ET. A live webcast and replay will be available on the company's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
none
-
Rhea-AI Summary

Treace Medical Concepts (TMCI) reported Q3 2024 financial results with revenue of $45.1 million, up 11% year-over-year. The company posted a net loss of ($15.4) million, improving from ($17.5) million in Q3 2023. Adjusted EBITDA loss improved 45% to ($5.1) million from ($9.2) million year-over-year. The company announced entry into the high-volume osteotomy market with Nanoplasty™ 3D Minimally Invasive Bunion Correction™ Procedure. Gross margin was 80.1%. Cash position stood at $82.8 million as of September 30, 2024. The company revised its full-year 2024 revenue guidance to $204-211 million, representing 9-13% growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.07%
Tags
-
Rhea-AI Summary

Treace Medical Concepts (NasdaqGS: TMCI), a medical technology company specializing in surgical treatments for bunions and midfoot deformities through its Lapiplasty® and Adductoplasty® Procedures, announced its participation in the upcoming UBS Global Healthcare Conference. CEO John T. Treace and CFO Mark L. Hair will engage in a fireside chat on November 12, 2024, at 11:45 am ET. The event will be accessible via live webcast and replay on the company's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.08%
Tags
none
Rhea-AI Summary

Treace Medical Concepts has announced significant reimbursement rate increases for its Lapiplasty® procedure following CMS' 2025 Final Rule. The CPT code 28297, used for Lapidus fusion and Lapiplasty® procedures, will be reassigned to APC code 5115, resulting in an 89% increase in hospital outpatient payment rates to $12,867 (up $6,050 from 2024). In the ASC setting, the payment will increase by 100% to $9,820, compared to $4,900 in 2024. These changes will take effect January 1, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.6%
Tags
none
-
Rhea-AI Summary

Treace Medical Concepts (TMCI) has announced the market release of the Nanoplasty™ 3D Minimally Invasive Bunion Correction™ System, marking its entry into the metatarsal osteotomy segment. This segment represents approximately 70% of the 450,000 annual bunion surgeries in the U.S. The new system performs bunion correction through a 1.5-centimeter hidden incision on the foot's side. Full commercialization is expected in the first half of 2025. This launch expands Treace's presence in the $5B+ US bunion market, complementing their existing Lapiplasty® and Adductoplasty® procedures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.6%
Tags
none
-
Rhea-AI Summary

Treace Medical Concepts, Inc. (NasdaqGS: TMCI), a medical technology company specializing in surgical treatments for bunions and midfoot deformities, has announced it will release its third quarter 2024 financial results after market close on Tuesday, November 5, 2024. The company will host a conference call at 4:30 pm ET to discuss the results.

Investors can participate in the call by registering to receive dial-in numbers and a unique pin. Additionally, a live and archived webcast of the event will be available on the company's investor relations website at https://investors.treace.com/.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.33%
Tags
conferences earnings
Rhea-AI Summary

Treace Medical Concepts, Inc. (NASDAQ: TMCI) has filed a lawsuit against Stryker and its subsidiary Wright Medical Technology, Inc. (NYSE: SYK) for alleged patent infringement and unfair competition. The suit, filed in the U.S. District Court for the District of New Jersey, claims infringement of 9 patents related to Treace's Lapiplasty® 3D Bunion Correction® technologies.

Treace, a pioneer in 3D bunion correction systems, seeks injunctive relief and damages. CEO John T. Treace emphasized the company's role in creating a new segment in the US bunion market and its commitment to protecting intellectual property. He stated that the lawsuit aims to deter competitors from infringing on Treace's patents and reassure shareholders of the company's dedication to innovation.

Despite the legal action, Treace maintains its financial outlook, expecting a 50% improvement in 2024 Adjusted EBITDA compared to 2023 and anticipating Adjusted EBITDA breakeven in 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
-
Rhea-AI Summary

Treace Medical Concepts (NASDAQ: TMCI) will showcase new product innovations and present updated clinical data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2024. The company will highlight:

  • Nanoplasty™ MIS 3D Osteotomy System for minimally invasive bunion correction
  • IntelliGuide™ PSI Cut Guides for personalized surgical planning
  • Mini-Adductoplasty™ Guides for less-invasive midfoot correction
  • New SpeedPlate™ innovations for midfoot and rearfoot fusion
  • Micro-Lapiplasty™ Minimally Invasive System for small incision procedures

The company will also present interim data from the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies, demonstrating sustained positive outcomes at 3-4 years and 1-2 years post-procedure, respectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
-
Rhea-AI Summary

Treace Medical Concepts, Inc. (TMCI), a medical technology company specializing in bunion and midfoot deformity treatments, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's CEO, John T. Treace, and CFO, Mark L. Hair, will engage in a fireside chat on September 5, 2024, at 10:00 am ET.

Investors can access a live webcast and replay of the event through Treace's investor relations website. The company encourages stakeholders to regularly check their website for important updates and information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
none
Rhea-AI Summary

Treace Medical Concepts (NASDAQ: TMCI) reported its Q2 2024 financial results, showing revenue growth of 6% to $44.5 million compared to Q2 2023. The company's gross margin was 80.2%, slightly down from 81.7% in the previous year. Despite revenue growth, Treace faced a net loss of $21.2 million, or ($0.34) per share, wider than the $12.3 million loss in Q2 2023. The increased loss was attributed to higher operating expenses, which rose to $57.1 million from $47.3 million year-over-year. Treace maintains a strong cash position of $97.0 million and reaffirmed its full-year 2024 revenue guidance of $201-$211 million, representing 7-13% growth. The company expects Adjusted EBITDA to improve by approximately 50% compared to 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags

FAQ

What is the current stock price of Treace Medical Concepts (TMCI)?

The current stock price of Treace Medical Concepts (TMCI) is $6 as of October 13, 2025.

What is the market cap of Treace Medical Concepts (TMCI)?

The market cap of Treace Medical Concepts (TMCI) is approximately 371.5M.
Treace Medical Concepts, Inc.

Nasdaq:TMCI

TMCI Rankings

TMCI Stock Data

371.46M
46.95M
25.64%
61.21%
5.04%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
PONTE VEDRA